Hepion Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HEPA | PCSA | ASMB | ALGS | BIVI | RNTX | |
|---|---|---|---|---|---|---|
| Market cap | 16.63M | 5.41M | 404.57M | 31.35M | 11.63M | 56.82M |
| P/E (TTM) | — | — | 19.1 | — | — | — |
| Forward P/E | 0.0 | -0.5 | -7.7 | -1.0 | -2.4 | — |
| Price/book | -9.6 | -17.0 | 1.3 | 1.0 | 1.0 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +105.71% | −75.51% | −36.33% | −29.30% | −10.67% | −57.76% |
| Today | −6.25% | −0.26% | −0.25% | +5.68% | −22.54% | −1.32% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HEPA news ›Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
FDA's Division of Psychiatry issued written responses to a Type B pre-IND meeting request covering the regulatory pathway, the nonclinical package, and the design of a plan
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
The acquired programs bring Hepion's portfolio to three assets, alongside its in-licensed circulating tumor RNA diagnostic. Hepion Pharmaceuticals (HEPA) completed its acquisition of Gravitas Life Sciences on October 6, 2026, adding two…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.